Disc Medicine, Inc. (NASDAQ: IRON) is a clinical-stage biopharmaceutical company developing therapies for hematologic diseases caused by dysregulated iron homeostasis. Its pipeline targets both rare and chronic blood disorders with novel mechanisms of action. Disc Medicine’s shares move with clinical trial results, regulatory updates, and investor sentiment toward innovative rare-disease treatments.